Table 1.
Baseline characteristics of patients by biosimilar use status and overall
| Characteristic | Infliximab-dyyb (n = 870) | Infliximab (n = 2336) | Overall (n = 3206) | P |
|---|---|---|---|---|
| Age, mean (SD), y | 44.7 (16.6) | 44.1 (17.0) | 44.3 (16.9) | .28 |
| Female, No. (%) | 417 (47.9) | 1199 (51.3) | 1616 (50.4) | .09 |
| Race, No. (%) | .40 | |||
| White | 559 (64.3) | 1514 (64.8) | 2073 (64.7) | |
| Black | 73 (8.4) | 240 (10.3) | 313 (9.8) | |
| Hispanic | 123 (14.1) | 290 (12.4) | 413 (12.9) | |
| Asian | 69 (7.9) | 174 (7.4) | 243 (7.6) | |
| Other | 46 (5.3) | 118 (5.1) | 164 (5.1) | |
| CCI score, No. (%) | <.01 | |||
| 0 | 578 (66.4) | 1344 (57.5) | 1922 (60.0) | |
| 1 | 184 (21.1) | 625 (26.8) | 809 (25.2) | |
| 2 or higher | 108 (12.4) | 367 (15.7) | 475 (14.8) | |
| IBD type, No. (%) | .59 | |||
| Crohn’s disease | 387 (44.5) | 1064 (45.5) | 1451 (45.3) | |
| Ulcerative colitis | 483 (55.5) | 1272 (54.5) | 1755 (54.7) | |
| IBD disease duration, median (IQR), y | 2.1 (0.4–7.3) | 3.1 (0.7–8.6) | 2.8 (0.6–8.3) | <.01 |
| IBD-related surgeries within past 2 years, No. (%) | 156 (17.9) | 264 (11.3) | 420 (13.1) | <.01 |
| IBD-related ER visits within past 6 months, No. (%) | 85 (9.8) | 191 (8.2) | 276 (8.6) | .15 |
| IBD-related hospitalizations within past 6 months, No. (%) | 152 (17.5) | 444 (19.0) | 596 (18.6) | .32 |
| IBD medication history, No. (%) | ||||
| Aminosalicylates | 486 (55.9) | 1215 (52.0) | 1701 (53.1) | .05 |
| Budesonide | 143 (16.4) | 287 (12.3) | 430 (13.4) | <.01 |
| Immunomodulators | 618 (71.0) | 1533 (65.6) | 2151 (67.1) | <.01 |
| Corticosteroids | 499 (57.4) | 1113 (47.6) | 1612 (50.3) | <.01 |
| Dose of infliximab at index date, mean (SD), mg | 428 (138) | 421 (143) | 423 (141) | .01 |
Abbreviations: CCI, Charlson comorbidity index; ER, emergency room; IBD, inflammatory bowel disease; IQR, interquartile range; y, year.